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Random glucose sampling as screening
tool for diabetes among disadvantaged
tuberculosis patients residing in urban
slums in India
To the Editor:
Noncommunicable diseases like diabetes are increasingly recognised as important risk factors for
tuberculosis (TB) and poor treatment outcomes [1]. While the link between TB and diabetes was
described many decades ago, several recent epidemiological studies and systematic reviews have confirmed
the association of diabetes with a three-fold increased risk of developing TB [2]. Since 2011, the World
Health Organization has recommended bidirectional screening of all TB patients for diabetes [3].
However, it is currently unclear at which point in treatment one should screen and which diagnostic tools
should be used. Following the American Diabetes Association, diabetes is diagnosed by a fasting plasma
glucose ⩾7 mmol·L−1, a 2-h plasma glucose value ⩾11.1 mmol·L−1 during the oral glucose tolerance test,
glycated haemoglobin (HbA1C) ⩾48 mmol·mol−1 or a random plasma glucose value ⩾11.1 mmol·L−1 in
patients with classic symptoms of hyperglycaemia [4]. The Concurrent Tuberculosis and Diabetes Mellitus
(TANDEM) consortium recently suggested a simplified two-step diagnostic algorithm where all patients
with random plasma glucose levels >6.1 mmol·L−1 receive point-of-care HbA1C testing [4]. With
laboratory-based HbA1C as the gold standard, this two-step combination resulted in a sensitivity and
specificity of >90% to detect diabetes. Here, we evaluate the feasibility of diabetes screening by random
glucose sampling among disadvantaged TB patients residing in urban slums in New Delhi, India.
India has the highest TB burden worldwide, with 1.9 million cases notified in 2017 and an incidence rate
of 204 cases per 100000 population [5]. Considering that an estimated 11% of urban and 3% of rural
people above age 15 years have diabetes, the Revised National Tuberculosis Control Programme (RNTCP)
of India recommends bidirectional screening as well as prioritised case finding among contacts with
diabetes [6]. Diabetes screening among TB patients registered under the RNTCP yielded a prevalence of
11.9% [7]; however, no information is available on patients who are treated outside the RNTCP. Operation
ASHA (OpASHA), a not-for-profit nongovernmental organisation (NGO) founded in 2006, is dedicated to
bringing free TB treatment to disadvantaged patients in urban slums and poor rural communities that
might otherwise not be able to seek treatment through private entities or the RNTCP. OpASHA currently
serves 20 million people in six Indian states, in eight Cambodian provinces and in Afghanistan. They have
a team of 292 field workers, 150 community partners and ∼4000 village healthcare workers. A biometric
attendance terminal is employed using fingerprints to identify patients and healthcare workers during
treatment visits. Using an Android (Google LLC, Mountain View, CA, USA) application that features
automated mobile telephone messaging to patients in case of missed visits as well as digitised records,
OpASHA has markedly improved treatment adherence, with few missed doses among its patients.
OpASHA-treated patients achieve high treatment outcomes with less initial treatment default than the
national TB programme [8, 9].
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Recently, a two-step diagnostic algorithm to diagnose diabetes among TB patients was proposed
comprising random glucose and point-of-care HbA1c. This study evaluates the first part of this
algorithm among disadvantaged TB patients. http://ow.ly/UI7d30nK1UN
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Here, we aimed to investigate the feasibility of random glucose sampling, the first step of the two-step
diagnostic approach proposed by the TANDEM consortium, among this difficult-to-reach patient
population. OpASHA initiated a pilot intervention in its TB treatment centres in East, West and South
Delhi consisting of training staff to measure blood glucose and to provide appropriate diabetes counselling,
as well as distribution of glucometers, and test kit supply and minor infrastructure investments.
Glucometers were procured from Accu-Check (Glucometers, Active Test strips and retractable Uno
Lancets; all Roche Diagnostics, Basel, Switzerland). Endocrinologists practicing in proximity to the Delhi
slum areas agreed to manage patients diagnosed with possible diabetes. Patients who did not want to be
tested for diabetes continued to receive TB treatment and care.
Between 2013 and 2015, a total of 1773 patients were screened for diabetes by trained OpASHA personnel
(table 1). We identified a total of 336 (19%) patients with random glucose levels >6.1 mmol·L−1 who
qualified to receive point-of-care HbA1c testing to confirm diabetes following the TANDEM two-step
algorithm, which was, however, not available in the OpASHA treatment centres [4]. Among these patients,
66 (4% of total) were found to have diabetes based on glucose levels >11.1 mmol·L−1. Of these 66 patients,
20 were known diabetics and already on treatment. The remaining patients were referred to one of the
collaborating endocrinologists for further diagnostics and treatment. Increasing age was significantly
associated with elevated glucose levels (table 1). Male sex was slightly overrepresented in our screening
population but not linked to increased glucose values (table 1). Most of the screened TB patients were
treated for pulmonary TB (68%). The majority (86.0%) of these were new diagnoses with the remaining
being previously treated cases.
Our investigation shows that random glucose sampling is a feasible and simple tool to implement in
resource-poor settings with disadvantaged communities once appropriate training of staff is achieved. We
found high numbers of patients with elevated random glucose levels. However, to accurately diagnose
diabetes in this setting and to follow the TANDEM diagnostic algorithm, local point-of-care HbA1c
testing is indispensable and future efforts should focus on implementing this second step of the TANDEM
approach in such settings. Limitations of this study include challenging data collection that resulted in
missing data and incorrect data entry in a few cases. The voluntary nature of the glucose measurement
could be subject to unaccounted selection bias. It is important to provide diabetes screening to all TB
patients, notably vulnerable TB patients that reside in slums, villages and hard-to-reach areas that are not
under treatment through a national TB programme. Both national programmes and NGOs caring for TB
patients should therefore implement routine diabetes screening using random glucose sampling as a first
step with point-of-care HbA1c as confirmation to identify undetected diabetes cases.
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TABLE 1 Descriptive statistics
Patient characteristics Random plasma glucose All patients
⩽6.1 mmol·L−1 >6.1–⩽11.1 mmol·L−1 >11.1 mmol·L−1
Patients n 1437 270 66 1773
Age years median (IQR) 27*** (21–38) 42*** (30–50) 47.5*** (42–51) 30 (22–43)
Sex proportion
Female 0.43# 0.41# 0.44# 0.43
Male 0.56# 0.59# 0.56# 0.57
In nine instances, the glucose results were excluded due to probably erroneous entries (>27.8 mmol·L−1);
for five entries, sex information was unavailable. The Wilcoxon signed-rank nonparametric test was used
for the variables age and sex. IQR: interquartile range. #: nonsignificant; ***: p<0.001.
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